From CEO Fiona Wardman, HAE Australasia:

Patients in Australia are thankful for our Health Minister’s decision to sign off on the recommendation to fund Takhzyro (lanadelumab). As of 1 December 2021, more patients have access to this treatment, closing the gap of access for prophylaxis medications for many of our patients.

Our patients in New Zealand also received some good news via a press release that Intellia’s Phase 1/2 study will be recruiting patients by the end of the year.

HAE Australasia looks forward to hosting two Patient and Carers Conferences in February 2022. The registration websites (utilizing HAEi’s Event Zoo application) are now open for the Australian meeting on 5 February and the New Zealand meeting on 26 February 2022. We are excited to connect face-to-face once again to have presentations from top physicians and experts on exciting subjects and network.

The Board of HAE Australasia will convene early in the new year for a strategy meeting to work on plans and projects for 2022. We have some great ideas to discuss, and we look forward to bringing these to our patients of all ages and their family members.

HAE Australasia has seen an increase in HAE patients and their families becoming members of our organization. We welcome everyone to the group, and we look forward to meeting them in person soon. 

We wish everyone a Merry Christmas and all the best for a safe, happy, and healthy 2022.